Live from the NIH registry
Studies recruiting near Antioch right now
Top 25 of 445 recruiting studies, sorted by proximity — each links to its official registry page
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Kaiser Permanente Medical Center — Vallejo, California (26.5 mi)
· Sponsor: Relay Therapeutics, Inc.
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Obesity
Phase 3
Interventional 600 participants sought
Diablo Clinical Research, Inc. — Walnut Creek, California (15.5 mi)
· Sponsor: Novo Nordisk A/S
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Gout
Phase 3
Interventional 500 participants sought
West Coast Research — Dublin, California (20.6 mi)
· Sponsor: Crystalys Therapeutics
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Obesity, Knee Osteoarthritis (OA)
Phase 3
Interventional 400 participants sought
Diablo Clinical Research, Inc. — Walnut Creek, California (15.5 mi)
· Sponsor: Novo Nordisk A/S
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
N/A
Interventional 24,000 participants sought
Kaiser Permanente-Division of Research — Pleasanton, California (22.3 mi)
· Sponsor: National Cancer Institute (NCI)
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Phase 2
Interventional 270 participants sought
Diablo Clinical Research, Inc. — Walnut Creek, California (15.5 mi)
· Sponsor: Novo Nordisk A/S
Effect of Exercise on Body Composition and Bone Health in Patients With Thalassemia
Thalassemia
N/A
Interventional 20 participants sought
UCSF Benioff Children's Hospital Oakland — Oakland, California (28.6 mi)
· Sponsor: University of California, San Francisco
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Phase 2
Interventional 630 participants sought
Research Site — Oakland, California (28.6 mi)
· Sponsor: AstraZeneca
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer
Phase 3
Interventional 480 participants sought
Kaiser Permanente Medical Center — Vallejo, California (26.5 mi)
· Sponsor: ArriVent BioPharma, Inc.
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
Barrett Esophagus, Barretts Esophagus With Dysplasia
N/A
Interventional 2,298 participants sought
Kaiser Permanente — Oakland, California (28.6 mi)
· Sponsor: University of Colorado, Denver
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Hereditary Angioedema, HAE
Phase 3
Interventional 90 participants sought
ADARx Clinical Site — Walnut Creek, California (15.5 mi)
· Sponsor: ADARx Pharmaceuticals, Inc.
Study of Student Flourishing
Healthy
N/A
Interventional 2,500 participants sought
University of California, Berkeley — Berkeley, California (27.0 mi)
· Sponsor: Flourish Science, Inc.
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Ganglioneuroblastoma, Nodular, Neuroblastoma
Phase 3
Interventional 478 participants sought
UCSF Benioff Children's Hospital Oakland — Oakland, California (28.6 mi)
· Sponsor: National Cancer Institute (NCI)
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Phase 3
Interventional 582 participants sought
Research Site — Walnut Creek, California (15.5 mi)
· Sponsor: AstraZeneca
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NonSegmental Vitiligo
Phase 3
Interventional 180 participants sought
Golden State Dermatology — Walnut Creek, California (15.5 mi)
· Sponsor: Incyte Corporation
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Phase 3
Interventional 380 participants sought
Alta Bates Summit Medical Center for Research /ID# 261438 — Berkeley, California (27.0 mi)
· Sponsor: AbbVie
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
Phase 2
Interventional 93 participants sought
Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California (27.0 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Episodic Migraine
Phase 3
Interventional 450 participants sought
Sunwise Clinical Research /ID# 248529 — Walnut Creek, California (15.5 mi)
· Sponsor: AbbVie
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Phase 3
Interventional 1,450 participants sought
Eden Hospital Medical Center — Castro Valley, California (25.3 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
Graves Disease
Phase 3
Interventional 300 participants sought
Site-067 — Walnut Creek, California (15.5 mi)
· Sponsor: Biohaven Therapeutics Ltd.
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
Chronic Myelogenous Leukemia - Chronic Phase
N/A
Observational 1,000 participants sought
Stockton Hematology Oncology Medical Group Inc — Stockton, California (27.6 mi)
· Sponsor: Novartis Pharmaceuticals
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Phase 3
Interventional 508 participants sought
Clinical Research Site — Walnut Creek, California (15.5 mi)
· Sponsor: Axsome Therapeutics, Inc.
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
Amblyopia
Phase 3
Interventional 252 participants sought
Univ. of California- Berkeley — Berkeley, California (27.0 mi)
· Sponsor: Jaeb Center for Health Research
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Phase 3
Interventional 1,314 participants sought
Kaiser Permanente-Kaiser Permanente, Vallejo Medical Center, Adult Oncology ( Site 0101) — Vallejo, California (26.5 mi)
· Sponsor: Merck Sharp & Dohme LLC
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 2,000 participants sought
Kaiser Permanente-Walnut Creek — Walnut Creek, California (15.5 mi)
· Sponsor: National Cancer Institute (NCI)